We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DexCom (DXCM) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
In the latest trading session, DexCom (DXCM - Free Report) closed at $420.01, marking a -1.44% move from the previous day. This change lagged the S&P 500's daily loss of 1.23%. At the same time, the Dow lost 1.31%, and the tech-heavy Nasdaq lost 2.29%.
Heading into today, shares of the medical device company had gained 8.08% over the past month, outpacing the Medical sector's gain of 3.6% and the S&P 500's gain of 5.2% in that time.
Wall Street will be looking for positivity from DXCM as it approaches its next earnings report date. This is expected to be July 28, 2020. In that report, analysts expect DXCM to post earnings of $0.28 per share. This would mark year-over-year growth of 250%. Our most recent consensus estimate is calling for quarterly revenue of $406.09 million, up 20.72% from the year-ago period.
DXCM's full-year Zacks Consensus Estimates are calling for earnings of $2.23 per share and revenue of $1.78 billion. These results would represent year-over-year changes of +21.2% and +20.54%, respectively.
It is also important to note the recent changes to analyst estimates for DXCM. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.08% lower within the past month. DXCM is currently a Zacks Rank #3 (Hold).
Investors should also note DXCM's current valuation metrics, including its Forward P/E ratio of 191.1. Its industry sports an average Forward P/E of 47.61, so we one might conclude that DXCM is trading at a premium comparatively.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 153, which puts it in the bottom 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow DXCM in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DexCom (DXCM) Dips More Than Broader Markets: What You Should Know
In the latest trading session, DexCom (DXCM - Free Report) closed at $420.01, marking a -1.44% move from the previous day. This change lagged the S&P 500's daily loss of 1.23%. At the same time, the Dow lost 1.31%, and the tech-heavy Nasdaq lost 2.29%.
Heading into today, shares of the medical device company had gained 8.08% over the past month, outpacing the Medical sector's gain of 3.6% and the S&P 500's gain of 5.2% in that time.
Wall Street will be looking for positivity from DXCM as it approaches its next earnings report date. This is expected to be July 28, 2020. In that report, analysts expect DXCM to post earnings of $0.28 per share. This would mark year-over-year growth of 250%. Our most recent consensus estimate is calling for quarterly revenue of $406.09 million, up 20.72% from the year-ago period.
DXCM's full-year Zacks Consensus Estimates are calling for earnings of $2.23 per share and revenue of $1.78 billion. These results would represent year-over-year changes of +21.2% and +20.54%, respectively.
It is also important to note the recent changes to analyst estimates for DXCM. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.08% lower within the past month. DXCM is currently a Zacks Rank #3 (Hold).
Investors should also note DXCM's current valuation metrics, including its Forward P/E ratio of 191.1. Its industry sports an average Forward P/E of 47.61, so we one might conclude that DXCM is trading at a premium comparatively.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 153, which puts it in the bottom 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow DXCM in the coming trading sessions, be sure to utilize Zacks.com.